Surgical Oncology News

This section features a sampling of news related to surgical oncology from the popular press, from press releases received, or SSO news directly pertinent to SSO members.

Ipilimumab plus surgery boosted advanced melanoma survival

Author: Neil Osterweil, Oncology Report Digital Network
Date:
Apr 10, 2013

Patients with stage IV melanoma treated with a combination of ipilimumab and surgical resection had a high rate of melanoma-specific and overall survival, a retrospective study of a single-center case series has shown.

"To our knowledge, this is the first report of 5-year melanoma-specific survival data on patients who have undergone surgical resection and ipilimumab treatment, and the data suggests that surgical resection and ipilimumab treatment may result in long-term survival in select metastatic melanoma patients," Dr. Junko Ozao-Choy said at the annual Society of Surgical Oncology Cancer Symposium.

Among 44 patients treated with the CTLA-4 (cytotoxic T-lymphocyte antigen 4) inhibitor ipilimumab (Yervoy) and surgical resection, the 5-year melanoma-specific survival (MSS) rate was 51% and the median overall survival duration was 60 months, reported Dr. Ozao-Choy of the John Wayne Cancer Institute at Saint John’s Health Center in Santa Monica, Calif.

For 24 patients who received ipilimumab before resection, the 5-year MSS was 61% at a median of 60 months, and for 18 of 20 patients treated with ipilimumab after surgery, the 5-year MSS was 42% at a median of 47 months, but this difference was not significant (data were incomplete for 2 patients in the latter group), she noted.

Read More on This Story Here...

Read More Surgical Oncology News Stories...